Support Accelerated Approval of Drugs for Ultra-Rare Diseases to Benefit Vulnerable Patients, Promote Biotechnology Innovation and Stimulate Job Growth in the United States January 4, 2012 The Honorable Fred Upton, Chair

First Page		Document Content
Date: 2012-01-06 16:36:41 Neurodegenerative disorders Drug discovery Epidemiology Orphan drug Orphan Drug Act Niemann–Pick disease Batten disease FDA Fast Track Development Program Medical research Health Rare diseases Lipid storage disorders		Support Accelerated Approval of Drugs for Ultra-Rare Diseases to Benefit Vulnerable Patients, Promote Biotechnology Innovation and Stimulate Job Growth in the United States January 4, 2012 The Honorable Fred Upton, Chair Add to Reading List Source URL: www.curesarcoma.org Download Document from Source Website File Size: 23,09 KB Share Document on Facebook

	The NIH Undiagnosed Diseases Program J A M E S P A N • 10 J U N E 2014 Stanford University School of Medicine In the United States, a rare disease defined by the 1983 Orphan Drug Act, is a disease that aﬀects fewer DocID: 1uQtE - View Document
	Zusammenfassung der Master-Thesis von Rossella Belleli Efficiency indicators for new drugs approved by the FDA from 2003 toIn the last decades, the drug development costs have increased while the number of new dru DocID: 1pOAi - View Document
	Personalized Medicine and Companion Diagnostics: Shaping the Future of the Clinical Research Enterprise PEER REVIEWED \| Heather Harris, MSc [DOI: CR] DocID: 1p6bN - View Document
	Lhorne on DSK30JT082PROD with NOTICESFederal Register / Vol. 81, NoThursday, July 28, Notices DocID: 1oKKK - View Document
	© 2007 Nature Publishing Group http://www.nature.com/naturemedicine C O M M E N TA RY Aligning pharmaceutical innovation with medical need DocID: 1aC3u - View Document